AstraZeneca poaches new chief from rival to revive its fortunes
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.AstraZeneca poached its new chief executive from Swiss rival Roche yesterday in an attempt to kick-start the UK drugs giant, which will see many of its top-selling drugs come off patent in the next two years.
The company has also suffered a series of multi-million pound clinical trial failures.
Pascal Soriot, 53, who practised as a vet before moving into the pharmaceutical industry, will join AstraZeneca at the start of October. He headed the cancer drug group Genentech before its $100m (£63m) takeover by Roche in 2009, where he became head of pharmaceuticals. The Frenchman replaces David Brennan, who was one of the most high-profile casualties of the shareholder spring. Mr Brennan resigned in April hours before the company's annual meeting after coming under increasing pressure from institutional investors.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments